Evolus, Inc. (EOLS)
Nasdaq: EOLS · Pharmaceutical Preparations · Newport Beach, CA · filing with the SEC since 2013
Who owns Evolus, Inc.
As filed with the SECHolders of 5% or more
4
Timothy P. Lynch holds 9.9% of Common Stock, as its SCHEDULE 13G/A filed Feb 17, 2026 says.
Directors and officers
9
report now, of 20 people on the record since 2018. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 4 named at left.
Holders of 5% or moreshare of the class, as filed
Timothy P. Lynch
SCHEDULE 13G/A · filed Feb 17, 2026 · Common Stock · 7.9% in Nov 14, 2025
Nantahala Capital Management, LLC
SCHEDULE 13G/A · filed Nov 14, 2025 · Common Stock, par value $0.00001 per share · 5.9% in May 15, 2025
Blackrock, Inc.
SCHEDULE 13G/A · filed Feb 5, 2025 · Common Stock
Soleus Capital Master Fund, L.P.
SCHEDULE 13G · filed Aug 31, 2026 · Common Stock, par value $0.00001 per share
Perceptive Advisors LLC
SCHEDULE 13G/A · filed Aug 14, 2025 · Common Stock, $0.00001 par value per share · reported falling below 5%, from 6.4% in May 15, 2025
Medytox Inc.
SCHEDULE 13G/A · filed Feb 6, 2025 · Common stock, par value $0.00001 per share · reported falling below 5%
Tang Capital Management, LLC
SCHEDULE 13G/A · filed Feb 17, 2026 · Common Stock, par value $0.00001 per share · reported falling below 5%, from 7.9% in May 15, 2025
The Vanguard Group
SCHEDULE 13G/A · filed Mar 26, 2026 · Common Stock · reported falling below 5%
Caligan Partners LP
SCHEDULE 13G/A · filed Feb 17, 2026 · Common Stock, par value $0.00001 per share · reported falling below 5%, from 6.4% in Nov 14, 2025
What EOLS reports owning in othersstakes of 5% or more, and other ties
7 subsidiaries in 7 countries, from the list filed with the 10-K filed Mar 3, 2026.
Insider tradesForm 4
7sales
0purchases
5sales on a scheduled plan
2people selling
$1.8Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window2 of 23 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Moatazedi David | President and Chief Executive Officer | 4 | $1.7M | 3 | 0 | $0 |
| Avelar Rui | Chief Medical Officer and Head of Research & Development | 3 | $200,000 | 2 | 0 | $0 |